Laurus Labs Q2 results double profit as it buys into a peptide resin maker

Laurus Labs Q2 results show the Indian drugmaker more than doubling its quarterly profit while it buys into two small technology firms, one of them a maker of the resins used to build peptides. In a regulatory filing on 29 October 2026, the company reported consolidated net profit of Rs 441 crore for July to September, against Rs 195 crore a year earlier. It also agreed to take 52 per cent of SI&C Resins and 60 per cent of Galenvs Sciences in Montréal. The peptide angle is supply.

What Laurus Labs reported for the September quarter

The Laurus Labs Q2 results cover the second quarter of India's fiscal year 2027, which runs from April 2026 to March 2027. Revenue from operations rose 33 per cent to Rs 2,206 crore from Rs 1,653 crore, according to the PTI report carried by Rediff Money. For readers outside India, one crore equals ten million, so the quarterly profit is about Rs 4.41 billion. Earnings before interest, tax, depreciation and amortisation (EBITDA) reached Rs 762 crore, a rise of 78 per cent, and the EBITDA margin was 34.5 per cent. Chief financial officer V V Ravi Kumar credited both business lines. He said the margin was "supported by improvement in capacity efficiency from growing commercial supplies", which in his account means existing plants are running fuller.

The split between divisions explains most of the jump. The contract development and manufacturing (CDMO) division, which makes ingredients and drugs for other companies, earned Rs 904 crore in the quarter, up 75 per cent, according to a Free Press Journal summary of the exchange filings. The Affordable Medicines division, still the larger unit by sales, earned Rs 1,302 crore, up 15 per cent. Over the half year, net profit rose to Rs 809 crore from Rs 358 crore on revenue of Rs 4,233 crore. The board declared an interim dividend of Rs 1.00 per share. Research investment was Rs 65 crore in the quarter, or 2.9 per cent of revenue. Neither report split out peptide sales, so the filing does not show how much CDMO growth came from peptides.

Resin stake targets the raw materials of peptide chemistry

The smaller of the two deals sits closest to this desk's beat. Laurus signed a definitive agreement to buy 52 per cent of SI&C Resins, which it described as a company focused on peptide resin technology. In the usual chemical route for making peptides, the chain is built one amino acid at a time on tiny resin beads, then cut free and cleaned up on chromatography columns. Both steps depend on specialised materials, and a peptide plant cannot run without a steady flow of them. Our explainer on how GLP 1 peptides get made shows why tirzepatide style molecules rely fully on this chemistry, while the semaglutide backbone is grown in yeast before chemical finishing.

Laurus says owning most of SI&C Resins will bring solid support resins and chromatography media in house, which it expects to make its peptide supply more secure over time.

Laurus says owning most of SI&C Resins will bring solid support resins and chromatography media in house, which it expects to make its peptide supply more secure over time. The company also tied the SI&C Resins stake to cost, saying it adds to peptide manufacturing competitiveness. That is a company expectation, not a measured result. The statements reported did not give a price for the stake, the home country of SI&C Resins, its output, or when the deal will close. Other suppliers keep widening their own ranges, and DuPont recently added reverse phase silica to its peptide purification media. Whether a resin maker under majority control gives Laurus a real cost edge will depend on figures the company has not yet published, such as margins on purchased inputs.

Galenvs Sciences deal adds a Canadian oligonucleotide arm

The second agreement reaches into Canada. Laurus will take 60 per cent of Galenvs Sciences, a Montréal company that works on oligonucleotides and precision magnetic nanoparticles, according to the Free Press Journal account; the PTI report spells the name Galenvs Science. Oligonucleotides are short chains of DNA or RNA building blocks, not peptides, although they are also assembled step by step on a solid support. The deal is small in money terms. The newspaper reports that Laurus proposes to invest USD 3.75 million, including a primary infusion of USD 2.75 million, at a pre money valuation of USD 3.50 million. It adds that the investment is still subject to due diligence, so the purchase is not yet complete.

PTI quoted the company as saying the deal should expand its position in what it called the fast growing oligonucleotide market. That is the company's framing, and neither report gave sales or staff figures for Galenvs. For Canada, the deal places a Montréal research business under an Indian majority owner. Chief executive Satyanarayana Chava grouped the two purchases together, saying Laurus "made targeted investments in Oligonucleotides and peptide-resins technologies, elevating our integrated CDMO offering." Readers who followed Samsung Biologics and PolyPeptide have seen another large group choose to buy specialist capacity rather than build it alone. The Laurus deals are far smaller, but the logic of buying know how is similar.

Indian peptide CDMO plans and the open questions

The clearest peptide news inside the results is Chava's remark on Vizag, the port city of Visakhapatnam in Andhra Pradesh. He said Laurus "operationalised its first commercial-scale peptide plant in Vizag" and that "a significant capacity expansion is already under progress to address surging demand for peptide therapeutics." That puts a working Vizag peptide plant on the record, not just a project. For readers abroad, the point is how an Indian peptide CDMO earns money. It makes ingredients to another company's order and is paid for reliable delivery, so plant uptime and steady access to inputs such as resins count for as much as product approvals do for a generic seller.

Much remains unstated. The reports did not name the peptides made at Vizag, its customers, its capacity, the size or cost of the expansion, or a date for new lines. They also did not break out peptide revenue within the Rs 904 crore CDMO total. Phrases such as "surging demand" reflect the chief executive's view and are not a forecast this desk can test. What to watch next: the closing of the SI&C Resins and Galenvs deals after due diligence, any disclosure of what SI&C makes and where, and the third quarter filing, which may show whether peptide work becomes a reported line. The Laurus Labs Q2 results set a high base for that comparison.

Conclusion

Laurus Labs Q2 results pair a doubled profit with two small, targeted purchases. The filed numbers are clear: Rs 441 crore of net profit, Rs 2,206 crore of revenue and a CDMO division up 75 per cent. The peptide case rests on a newly running Vizag plant and a majority stake in a resin maker, both described without capacity, price or customer detail. Until Laurus discloses those figures, the supply and cost gains it describes remain its own expectations. This report is for research and industry readers, not investment or medical advice.